Piezotx provides a proprietary delivery platform, Piezopen, that uses piezoelectric pulses and microneedle electrodes to introduce naked RNA or DNA directly into cells without lipid nanoparticles or viral vectors. The pen‑like, low‑cost device enables localized, repeatable dosing with superior safety and manufacturing simplicity, supporting vaccines, immunotherapies, protein‑replacement and dermal gene‑therapy applications for pharma and biotech partners.
Funding
$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current nucleic acid medicines such as RNA and DNA therapeutics rely on complex delivery systems like lipid nanoparticles or viral vectors, which are expensive to manufacture, have limited safety and tolerability, and are difficult to scale or re‑dose.
Solution
Piezotx offers a proprietary delivery platform called Piezopen that uses piezoelectric pulses delivered through a microneedle electrode array to introduce “naked” RNA or DNA directly into cells. The technology eliminates the need for lipid formulations or viral carriers, providing a simple pen‑like device comparable in cost and convenience to a pre‑filled syringe. By creating transient pores in the cell membrane, Piezopen enables intracellular delivery without endosomal escape, supporting both RNA and DNA payloads of various sizes. This approach aims to improve safety, reduce manufacturing complexity, and enable localized, repeatable dosing for vaccines, therapeutic proteins, immunotherapies, and dermal gene therapies.
Target Audience
Primary customers are pharmaceutical and biotech companies developing RNA or DNA therapeutics—including vaccine developers, immuno‑oncology programs, chronic disease protein‑replacement projects, and dermatology gene‑therapy initiatives.
Features
- Piezoelectric pulse generator combined with microneedle electrode array for localized intracellular delivery
- Compatibility with both naked RNA and DNA, ranging from short mRNA to large plasmids and self‑amplifying constructs
- Formulation‑free administration eliminates lipid nanoparticles and viral vectors, reducing manufacturing cost and complexity
- Pen‑like, low‑cost device (1/10,000th the size and 1/1,000th the cost of traditional electroporation systems) suitable for point‑of‑care or large‑scale use
- Enables repeat dosing with minimal reactogenicity, supporting chronic disease and dermatology applications
- Scalable platform that can be integrated into vaccine, oncology, chronic protein‑therapy, and dermal gene‑therapy pipelines